康泰医学(300869) - 2024 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2024 is projected to be a loss of between 55 million and 105 million CNY, compared to a profit of 165.76 million CNY in the same period last year[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of between 74 million and 125 million CNY, compared to a profit of 149.75 million CNY in the same period last year[3] Market Conditions - The decrease in orders and profit margins is attributed to reduced market demand and intensified industry competition[5] Impairment and Inventory - The company has recognized impairment losses on certain products and raw materials, leading to the provision for inventory write-downs, which negatively impacts net profit[5] Reporting - The financial data presented is preliminary and will be detailed in the 2024 annual report[6]